Artículo
Racotumomab: an anti=idiotype vaccine related to N=glycolyl=containing=gangliosides: Preclinical and clinical data
Vazquez, Ana M.; Hernandez, Ana M.; Macias, Amparo; Montero, Enrique; Gomez, Daniel Eduardo
; Alonso, Daniel Fernando
; Gabri, Mariano Rolando
; Gomez, Roberto E.
Fecha de publicación:
10/2012
Editorial:
Frontiers Media
Revista:
Frontiers in Oncology
ISSN:
2234-943X
Idioma:
Inglés
Tipo de recurso:
Artículo publicado
Clasificación temática:
Resumen
Neu-glycolyl (NeuGc)-containing gangliosides are attractive targets for immunotherapy with anti-idiotype mAbs, because these glycolipids are not normal components of the cytoplasmic membrane in humans, but their expression has been demonstrated in several human malignant tumors. Racotumomab is an anti-idiotype mAb specific to P3 mAb, an antibody which reacts to NeuGc-containing gangliosides, sulfatides, and other antigens expressed in tumors. Preparations containing racotumomab were able to induce a strong anti-metastatic effect in tumor-bearing mice. Different Phase I clinical trials have been conducted in patients with advanced melanoma, breast cancer, and lung cancer. The results of these clinical trials demonstrated the low toxicity and the high immunogenicity of this vaccine. The induced antibodies recognized and directly killed tumor cells expressing NeuGcGM3. A Phase II/III multicenter, controlled, randomized, double blind clinical trial was conducted to evaluate the effect of aluminum hydroxide-precipitated racotumomab vaccine in overall survival in patients with advanced non-small cell lung cancer. The clinical results of this study showed a significant clinical benefit in the patients who were treated with the anti-idiotype vaccine.
Palabras clave:
RACOTUMOMAB
,
VACCINE
,
GANGLIOSIDES
,
CANCER
Archivos asociados
Licencia
Identificadores
Colecciones
Articulos(SEDE CENTRAL)
Articulos de SEDE CENTRAL
Articulos de SEDE CENTRAL
Citación
Vazquez, Ana M.; Hernandez, Ana M.; Macias, Amparo; Montero, Enrique; Gomez, Daniel Eduardo; et al.; Racotumomab: an anti=idiotype vaccine related to N=glycolyl=containing=gangliosides: Preclinical and clinical data; Frontiers Media; Frontiers in Oncology; 2; 10-2012; 1-6
Compartir
Altmétricas